Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) contiguous enactment successful 1 of the astir breathtaking maturation markets successful healthcare: the value nonaccomplishment cause market, 1 that's connected way to scope astir $100 cardinal successful a fewer years. Novo was the archetypal to motorboat GLP-1 drugs and spot them present blockbuster revenue, but it was rapidly followed by Lilly, and this institution besides saw large successes.

In fact, arsenic of astir a twelvemonth ago, Lilly really jumped up of Novo and is present the GLP-1 person successful the U.S. and internationally. This enactment has translated into double-digit gross maturation arsenic good arsenic banal terms performance, arsenic investors applauded Lilly's accomplishments.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

But close now, is 1 caller disturbing inclination atrocious quality for Lilly successful this cardinal maturation market? Let's find out.

Today's value nonaccomplishment drugs

So, first, a spot of inheritance connected these pharma companies' portfolios. Novo sells semaglutide nether the marque names Ozempic and Wegovy, for benignant 2 diabetes and value loss, respectively. Lilly sells tirzepatide arsenic Mounjaro for the erstwhile denotation and Zepbound for the latter. These drugs, successful injectable format, enactment connected hormonal pathways progressive successful digestion and truthful assistance modulate humor sweetener levels and appetite. Patients self-inject connected a play basis.

Demand has been precocious for these products, adjacent resulting successful shortages successful the past -- successful caller times, though, proviso has been capable to conscionable request since some companies ramped up manufacturing capacity.

The Novo and Lilly drugs person proven to beryllium efficacious and safe, and they are casual for patients to acceptable into their routines -- each of this has contributed to their popularity. Why has Lilly won enactment successful the market? It whitethorn beryllium owed to information showing that the Lilly drugs pb to greater value loss. In a head-to-head study, Zepbound helped patients suffer an mean of 20% of their assemblage weight, portion Wegovy generated mean value nonaccomplishment of 13% astatine 72 weeks.

But these aren't the lone value nonaccomplishment drugs sold by Lilly and Novo. Each has launched caller oral value nonaccomplishment drugs successful caller times, and these could correspond the adjacent question of maturation for the companies. Novo won support for oral Wegovy precocious past year, and Lilly won support for Foundayo, its oral GLP-1 drug, this spring.

Prescriptions for Foundayo